Recent Advances in Cancer Care: New Paradigms, Novel Agents and What It Means for the Oncology Nurse — Immunotherapeutic Approaches for Endometrial Cancer

Accreditation types: 1.5 NCPD

Expires: June 2027

To play this presentation please log in.

Don't have an account?

Nursing Symposium Video Proceedings

1h 28min

Faculty

Nurse

Sarah Karpen

MPAS, PA-C

Moores Cancer Center, UC San Diego Health, San Diego, California

APP Supervisor Medical Oncology, Division of Gynecologic Oncology

Faculty

J Alejandro Rauh-Hain

MD, MPH

The University of Texas MD Anderson Cancer Center, Houston, Texas

Associate Professor, Tenure Track, Deputy Division Head for Clinical Research, Division of Surgery, Dept of Gynecologic Oncology and Reproductive Medicine, Dept of Health Services Research

Nurse

Jaclyn Shaver

MS, APRN, CNP, WHNP

Stephenson Cancer Center, OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology

Moderator

Dana M Chase

David Geffen School of Medicine at UCLA, Los Angeles, California

Professor, Division of Gynecologic Oncology

TARGET AUDIENCE
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

PURPOSE STATEMENT
By providing information on the latest research developments in the context of expert perspectives, this NCPD activity will assist oncology nurses, nurse practitioners and clinical nurse specialists with the formulation of state-of-the-art clinical management strategies to facilitate optimal care of patients with endometrial cancer.

DESIRED LEARNING OUTCOME
At the conclusion of this activity, the learner will be able to self-report understanding of novel therapies for endometrial cancer and the management of associated treatment-related toxicities and a change to their practice related to properly addressing adverse events associated with novel oncology agents for patients with endometrial cancer.

At the end of the activity, learners will also be able to

Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with EC.
Appreciate available clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents and regimens.
Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

ACCREDITATION STATEMENT
Research To Practice (RTP) is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

CREDIT DESIGNATION STATEMENT
This educational activity for 1.5 contact hours is provided by RTP during the period of June 23, 2026, to June 23, 2027.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

ONCC/ILNA CERTIFICATION INFORMATION
The program content has been reviewed by the ONCC and is acceptable for recertification points. Learners must apply for NCPD credit to utilize this program for ONCC certification or renewal. To review certification qualifications please visit https://www.researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA

ONCC review is only for designating content to be used for ILNA points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

PRIVACY POLICY
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

HOW TO USE THIS NCPD ACTIVITY
To receive credit for this activity, the participant should review the NCPD information, watch the video, complete the post-test with a score of 80% or better, and fill out the evaluation.

CONTENT VALIDATION AND DISCLOSURES
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess relevant financial relationships with faculty, planners and managers of NCPD activities. Relevant financial relationships are identified and mitigated through a relevant financial relationship mitigation process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent nurse reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Rauh-Hain and Ms Shaver have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Karpen is on speakers bureaus for Amgen Inc.

MODERATOR — Dr Chase is on advisory committees with AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; has consulting agreements with AbbVie Inc, GSK; has contracted research with GSK, Merck; is on speakers bureaus for AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; and has nonrelevant financial relationships with NRG Oncology.

All of the relevant financial relationships above have been mitigated.

EDITOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: Aadi Bioscience, AbbVie Inc, ADC Therapeutics, Agendia Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Arvinas, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeOne, Biotheranostics Inc, A Hologic Company, Black Diamond Therapeutics Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Catalyst Pharmaceuticals Inc, Celcuity, Clovis Oncology, Coherus BioSciences, Corcept Therapeutics Inc, CTI BioPharma, a Sobi Company, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, Exact Sciences Corporation, Exelixis Inc, Genentech, a member of the Roche Group, Genmab US Inc, Geron Corporation, Gilead Sciences Inc, GSK, Helsinn Therapeutics (US) Inc, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Jazz Pharmaceuticals Inc, Johnson & Johnson, Karyopharm Therapeutics, Kite, A Gilead Company, Kura Oncology, Legend Biotech, Lilly, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Mural Oncology Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Nuvalent, Nuvation Bio Inc, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Revolution Medicines Inc, Rigel Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Pharma America, Summit Therapeutics, Syndax Pharmaceuticals, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, and Verastem Inc.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners (including Nurse Planner Sharon Cusanza, MSN, RN, NEA-BC, CHCP), scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

This activity is supported by educational grants from GSK and Merck.

Release date: June 2026
Expiration date: June 2027

There is no implied or real endorsement of any product by RTP or the American Nurses Credentialing Center.

Dr Rauh-Hain

León-Castillo A et al. Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on prognosis and benefit from adjuvant therapy. J Clin Oncol 2020;38(29):3388-97. Abstract

Luchini C et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: A systematic review-based approach. Ann Oncol 2019;30(8):1232-43. Abstract

Oaknin A et al. Safety and efficacy of the anti–PD-1 monoclonal antibody dostarlimab in patients with recurrent or advanced dMMR endometrial cancer. SGO 2020;Abstract LBA9

Vikas P et al. Therapeutic potential of combining PARP inhibitor and immunotherapy in solid tumors. Front Oncol 2020;10:570. Abstract

Westin SN et al. Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: The phase III DUO-E trial. J Clin Oncol 2023;42(3):283-99. Abstract

Dr Chase

Alabi F et al. Lenvatinib plus pembrolizumab versus chemotherapy in advanced endometrial cancer: Efficacy and safety insights. Cureus 2025;17(7). Abstract

Eskander RN et al. Pembrolizumab plus chemotherapy in advanced or recurrent endometrial cancer: Overall survival and exploratory analyses of the NRG GY018 phase 3 randomized trial. Nat Med 2025;31(5):1539-46. Abstract

Makker V et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: 5-year outcomes from the randomized, phase 3 Study 309/KEYNOTE-775. J Immunother Cancer 2026;14(2). Abstract

Makker V et al. Lenvatinib plus pembrolizumab in previously treated advanced endometrial cancer: Updated efficacy and safety from the randomized phase III Study 309/KEYNOTE-775. J Clin Oncol 2023;41(16):2904-10. Abstract

Powell MA et al. Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY). Gyn Oncol 2025;192:40-49. Abstract

Ms Karpen

Wang Y et al. Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis. JAMA Oncol 2019;5(7):1008-19. Abstract

for-nurses

Recent Advances in Cancer Care — New Paradigms, Novel Agents and What It Means for the Oncology Nurse: Immunotherapeutic Approaches for Endometrial Cancer

A Complimentary NCPD Symposium Held During the 51^st Annual ONS Congress

Program Schedule — Central Time

5:30 AM – 6:00 AM — Registration and Breakfast
6:00 AM – 7:30 AM — Educational Meeting

Location

San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, Texas
Hotel Phone: (210) 223-1000

Meeting Room

Grand Ballroom A-F (Third Floor)

No registration fee is charged for this event. For the in-person symposium in San Antonio, preregistration is required as seating is limited.

Faculty

Sarah Karpen

MPAS, PA-C

Moores Cancer Center, University of California San Diego Health, San Diego, California

APP Supervisor Medical Oncology, Division of Gynecologic Oncology

Faculty

J Alejandro Rauh-Hain

MD, MPH

The University of Texas MD Anderson Cancer Center Houston, Texas

Associate Professor, Tenure Track Deputy Division Head for Clinical Research, Division of Surgery Dept of Gynecologic Oncology and Reproductive Medicine Dept of Health Services Research

Faculty

Jaclyn Shaver

MS, APRN, CNP, WHNP

OU Health, Oklahoma City, Oklahoma

Section of Gynecologic Oncology, Stephenson Cancer Center

Moderator

Dana M Chase

David Geffen School of Medicine at UCLA, Los Angeles, California

Professor, Division of Gynecologic Oncology

Meeting space has been assigned to provide a symposium supported by GSK and Merck during the Oncology Nursing Society’s (ONS) 51st Annual Congress, May 13-17, 2026 in San Antonio, TX. The Oncology Nursing Society’s assignment of meeting space does not imply product endorsement.

Program Schedule — Central Time

5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 7:30 PM — Educational Meeting

MODULE 1: Biology of Endometrial Cancer (EC); Rationale for the Use of Immune Checkpoint Inhibitors

Historical role of and outcomes achieved with chemotherapy as first-line treatment for patients with primary advanced or recurrent EC
Similarities and differences among the currently available anti-PD-1/PD-L1 antibodies for EC, such as dostarlimab, pembrolizumab and durvalumab
Biological rationale for the evaluation of anti-PD-1/PD-L1 antibodies in combination with chemotherapy for patients with EC
Frequency of potential biomarkers of response to immune checkpoint inhibitors in EC (eg, microsatellite instability [MSI]/mismatch repair [MMR] deficiency, POLE mutations); optimal approach to biomarker assessment for patients with newly diagnosed disease

MODULE 2: First-Line Therapy for Advanced or Recurrent EC

Key efficacy findings with dostarlimab, pembrolizumab and durvalumab, respectively, in combination with chemotherapy as first-line treatment for advanced or recurrent EC
Impact of MSI/MMR status on outcomes with the addition of anti-PD-1/PD-L1 antibodies to chemotherapy
FDA approvals of dostarlimab and pembrolizumab in combination with chemotherapy for patients with advanced or recurrent EC regardless of MSI/MMR status and of durvalumab in combination with chemotherapy for those with MMR-deficient disease
Optimal incorporation of anti-PD-1/PD-L1 antibodies into up-front therapy for patients with advanced or recurrent EC

MODULE 3: Potential Benefits of PARP Inhibition Combined with Immunotherapy for Advanced EC

Mechanism of antitumor activity of PARP inhibitors and biological rationale for their investigation in EC; potential therapeutic synergy between PARP inhibitors and immune checkpoint inhibitors
Benefits observed with first-line dostarlimab and carboplatin/paclitaxel followed by dostarlimab/niraparib maintenance compared to carboplatin/paclitaxel alone in advanced or recurrent EC
Published efficacy and safety results with durvalumab in combination with chemotherapy followed by durvalumab and olaparib maintenance for patients with newly diagnosed advanced or recurrent EC
Potential role of anti-PD-1/PD-L1 antibodies in combination with PARP inhibitors in the care of patients with EC

MODULE 4: Tolerability and Other Practical Considerations with Anti-PD-1/PD-L1 Antibodies for Previously Untreated Advanced EC

Pathophysiology, incidence and spectrum of immune-mediated and other adverse events (AEs) observed with anti-PD-1/PD-L1 antibodies in advanced EC
Recommended monitoring and management approaches for immune-related and other AEs with immune checkpoint inhibitors
Strategies to discern whether toxicities stem from anti-PD-1/PD-L1 antibodies or their therapeutic partners (eg, chemotherapy, PARP inhibitors) when these agents are administered in combination
Role of rechallenge in treatment for patients for whom immune checkpoint inhibitor therapy has been held due to immune-mediated toxicity
Relative and absolute contraindications to anti-PD-1/PD-L1 antibody therapy; role, if any, in treatment for patients with preexisting autoimmune conditions or a history of solid organ transplant

MODULE 5: Role of Lenvatinib/Pembrolizumab in the Management of Progressive Advanced EC

Biological rationale for combining immune checkpoint inhibitors with agents targeting the VEGF pathway in EC
Long-term findings, including overall survival data, supporting the use of lenvatinib in combination with pembrolizumab for patients with MMR-proficient advanced EC with disease progression after prior systemic therapy
Optimal integration of lenvatinib/pembrolizumab into EC management algorithms
Utility of lenvatinib/pembrolizumab among patients who have experienced disease progression on up-front chemoimmunotherapy

MODULE 6: Toxicities with Lenvatinib/Pembrolizumab

Incidence, severity, timing and management of AEs observed in patients with EC receiving lenvatinib/pembrolizumab (eg, hypertension, gastrointestinal issues, weight loss, hand-foot syndrome)
Approaches to encourage adequate nutrition among patients receiving the combination of lenvatinib and pembrolizumab
Initial dosing and dose-modification strategies for lenvatinib/pembrolizumab in EC; available data exploring the impact of lenvatinib dose reductions on antitumor activity
Strategies to determine the cause of toxicities that could stem from either lenvatinib or pembrolizumab among patients receiving the combination

Target Audience
This activity has been designed to meet the educational needs of oncology nurses, nurse practitioners and clinical nurse specialists involved in the treatment of endometrial cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

Evaluate the importance of microsatellite instability (MSI) and mismatch repair (MMR) deficiency assessment for patients with endometrial cancer (EC).
Appreciate available clinical research findings with the use of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent EC, and educate patients with MSI-high/MMR-deficient or microsatellite-stable/MMR-proficient disease about this novel strategy.
Understand the biological rationale for and available data with PARP inhibitors in combination with immune checkpoint inhibitor therapy for patients with advanced or metastatic EC, and reflect upon the potential role of this novel strategy.
Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and counsel patients with metastatic EC about the risks and benefits of this approach.
Appreciate the side effects associated with various systemic therapies commonly employed in the treatment of EC, and use this information to develop supportive management plans for patients undergoing treatment with these agents/regimens.
Describe the scientific justification for, published research data with and current studies of novel agents and strategies for EC, and effectively prioritize clinical trial opportunities for eligible patients.

Accreditation Statement
Research To Practice is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s (ANCC) Commission on Accreditation.

Credit Designation Statements
This educational activity for 1.5 contact hours is provided by Research To Practice.

This activity is awarded 1.5 ANCC pharmacotherapeutic contact hours.

Oncology Nursing Certification Corporation (ONCC)/Individual Learning Needs Assessment (ILNA) Certification Information
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points. To review certification qualifications please visit https://researchtopractice.com/Meetings/ONS2026/EndometrialCancer/ILNA.

ONCC review is only for designating content to be used for recertification points and is not for NCPD accreditation. NCPD programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the NCPD provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification or ILNA categories may be used in relation to the program.

Credit Form
To obtain a certificate of completion and receive credit for this event, nurses must attend the entire activity and return a completed Educational Assessment and Credit Form. A credit form link will be given to each participant as part of the meeting course materials.

Privacy Policy
Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.

Unlabeled/Unapproved Uses Notice
There is no implied or real endorsement of any product by Research To Practice or the American Nurses Credentialing Center.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant financial relationships will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — Ms Shaver and Dr Rauh-Hain have no relevant financial relationships to disclose. The following faculty reported relevant financial relationships with ineligible entities:

Ms Karpen — Speakers Bureaus: Amgen Inc.

MODERATOR — Dr Chase — Advisory Committees: AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Merck; Consulting Agreements: AbbVie Inc, GSK; Contracted Research: GSK, Merck; Speakers Bureaus: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, GSK, Pfizer Inc; Nonrelevant Financial Relationships: NRG Oncology.

RESEARCH TO PRACTICE NCPD PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS
Planners, scientific staff and independent reviewers for Research To Practice have no relevant financial relationships to disclose.

Supporters
This activity is supported by educational grants from AbbVie Inc, AstraZeneca Pharmaceuticals LP, Corcept Therapeutics Inc, and Merck.

Location
San Antonio Marriott Rivercenter
101 Bowie St
San Antonio, TX 78205
Hotel Phone: (210) 223-1000

Meeting Room
Grand Ballroom A-F (Third Floor)

Directions
The Marriott Rivercenter hotel is conveniently located within walking distance (1.5 blocks) of the Henry B González Convention Center, where the 2026 ONS Congress is taking place.

Registration is now closed.